Differentiated Thyroid Cancer

• FDA approval · 2022-09-16
  FDA Approved: LEVOTHYROXINE SODIUM — Supplemental Application (Accord Healthcare Inc.)

  The FDA approved a supplemental application for Accord Healthcare's levothyroxine sodium, a generic thyroid hormone replacement product.

• CLINICAL_TRIALS approval · 2016-03-16
  Clinical Trial Update: An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer

  Eisai's lenvatinib expanded access program for radioiodine-refractory differentiated thyroid cancer has resulted in marketing approval for t…

• FDA approval · 2015-07-31
  FDA Approved: HICON — Supplemental Application (Jubilant DraxImage Inc., dba Jubilant Radiopharma)

  FDA approved a supplemental application for HICON (Sodium Iodide I-131) from Jubilant Radiopharma, resulting in updated labeling for this ra…

• FDA approval · 2012-12-14
  FDA Approved: THYROGEN — Supplemental Application (Genzyme Corporation)

  FDA approved a supplemental application for THYROGEN (thyrotropin alfa) submitted by Genzyme Corporation. The action updates the product lab…